Europska Unija - hrvatski - EMA (European Medicines Agency)

vétoquinol sa - emodepside, praziquantel, tigolaner - Антгельминтики, - mačke - for cats with, or at risk from, mixed parasitic infestations. the veterinary medicinal product is exclusively indicated when ectoparasites, cestodes and nematodes are targeted at the same time.

Europska Unija - hrvatski - EMA (European Medicines Agency)

argenx - efgartigimod alfa - myasthenia gravis - imunosupresivi - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

guerbet, b.p. 57400, roissy cdg cedex, francuska - etilni esteri jodiranih masnih kiselina ulja sjemenki maka - otopina za injekciju - urbroj: svaki ml otopine sadrži 1280 mg etilnih estera jodiranih masnih kiselina ulja sjemenki maka što odgovara 480 mg joda

Europska Unija - hrvatski - EMA (European Medicines Agency)

extrovis eu ltd. - lakozamida - epilepsija - antiepileptici sredstva, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

ucb pharma sa - lakozamida - epilepsija - antiepileptici sredstva, - vimpat je indiciran kao monoterapija i pomoćna terapija u liječenju parcijalnih napadaja s ili bez sekundarne generalizacije kod odraslih, adolescenata i djece od 4 godine s epilepsijom.

Europska Unija - hrvatski - EMA (European Medicines Agency)

accord healthcare s.l.u. - lakozamida - epilepsija - antiepileptici sredstva, - lacosamide accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. lacosamide accord is indicated as adjunctive therapy•         in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. •         in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

medochemie ltd., constatinoupoleos str. 1-10, limassol, cipar - lakozamid - filmom obložena tableta - 100 mg - urbroj: jedna filmom obložena tableta sadrži 100 mg lakozamida

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

medochemie ltd., constatinoupoleos str. 1-10, limassol, cipar - lakozamid - filmom obložena tableta - 150 mg - urbroj: jedna filmom obložena tableta sadrži 150 mg lakozamida

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

medochemie ltd., constatinoupoleos str. 1-10, limassol, cipar - lakozamid - filmom obložena tableta - 200 mg - urbroj: jedna filmom obložena tableta sadrži 200 mg lakozamida